Carolina Cannabinoid Collaborative 2017 Annual Conference

RTI is proud to host the Carolina Cannabinoid Collaborative (CCC) 2017 Annual Conference. It is an exciting time in the field of cannabinoid and cannabis research. With everchanging policies and therapeutic potentials, the need for such research has never been more important. In this spirit, the 2017 CCC conference will showcase recent cutting-edge data from some of today’s top researchers. We hope that all participants learn something new, make connections, and develop collaborations during the conference.

Sponsors include RTI, La Jolla Alcohol Research, Inc., and the Lambert Center for the Study of Medicinal Cannabis and Hemp at Thomas Jefferson University. RTI’s Brian Thomas, Tim Lefever, and Tom Gamage comprise the 2017 CCC Planning Team, with Dr. Thomas serving as this year’s lead researcher.

RTI Press and Elsevier will be on hand to feature “The Analytical Chemistry of Cannabis: Quality Assessment, Assurance, and Regulation of Medicinal Marijuana and Cannabinoid Preparations.” The book was the first volume in the “Emerging Issues in Analytical Chemistry” series that the two publishers have collaborated on since 2015.

Pre-Conference Event

Prior to the opening of the CCC Conference, RTI will host the 2017 Allosteric Modulator Symposium. On October 27, from 11:45 a.m. to 4:30 p.m., CCC attendees are invited to join us at RTI’s Research Triangle Park headquarters as we delve into the topic of allosteric modulators.

As part of the symposium, the RTI Fellow Seminar Series is pleased to welcome Dr. Michelle Glass of the University of Auckland. Dr. Glass will discuss how “Allosteric Modulators Uncover Non-Arrestin Mediated Desensitization and Internalization of CB1.” Dr. Glass is a molecular neuropharmacologist with a strong focus on therapies targeting G-protein coupled receptors. She is particularly interested in the cannabinoid receptors and endocannabinoid system and their role in neurodegenerative disease and cancer.

Also at the symposium, Dr. Terry Kenakin of the University of North Carolina at Chapel Hill, who will present “Modifying Ongoing Chemical Conversations in the Body: The Promise of Allosteric Modulator Drugs.” Dr. Patti Reggio of the University of North Carolina at Greensboro will discuss “Signaling-Specific Allosteric Modulators of the Cannabinoid CB1 Receptor: Pregnenolone and Its Non-Steroidal Analogues.”

Seats for the symposium are limited, so please register by October 25.